Christopher R. Fenimore is VP & Controller at REGENERON PHARMACEUTICALS, INC. (REGN). They have made 10 open-market trades across 1 company since 2018, most recently 2026-08-18.
CIK 0001697422
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| REGN | 21,726 | $20.2M |
Shares reported on the most recent Form 4, priced at the 2026-11-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| REGN | SELL | 2024-08-28 | 2024-08-29 | $1205.26 | $13.0M | -3.2% | -10.9% | -36.0% |
| REGN | SELL | 2024-02-09 | 2024-02-12 | $953.01 | $7.8M | +3.7% | +2.0% | +3.3% |
| REGN | SELL · 10b5-1 | 2023-12-27 | 2023-12-29 | $856.71 | $4.2M | +4.8% | +9.4% | +10.1% |
| REGN | SELL · 10b5-1 | 2023-12-21 | 2023-12-26 | $844.30 | $3.3M | +6.5% | +11.9% | +13.4% |
| REGN | SELL · 10b5-1 | 2023-03-23 | 2023-03-27 | $806.47 | $3.5M | +0.6% | -5.6% | -4.8% |
| REGN | SELL | 2022-10-05 | 2022-10-07 | $749.00 | $1.4M | -1.5% | +4.3% | +0.5% |
| REGN | SELL | 2022-10-03 | 2022-10-05 | $724.00 | $2.4M | -1.1% | -0.5% | -3.1% |
| REGN | SELL | 2021-08-23 | 2021-08-24 | $655.43 | $3.2M | +1.0% | -3.9% | -4.3% |
| REGN | SELL | 2020-07-21 | 2020-07-22 | $642.01 | $4.7M | +1.1% | -5.1% | -9.6% |
| REGN | SELL | 2020-06-16 | 2020-06-17 | $590.91 | $4.2M | +1.6% | +7.1% | -3.6% |
| REGN | SELL | 2020-04-01 | 2020-04-03 | $488.94 | $963K | +7.3% | +7.6% | +23.7% |
| REGN | SELL | 2019-12-13 | 2019-12-13 | $376.11 | $1.2M | +1.9% | +3.0% | +17.4% |
| REGN | SELL | 2018-12-20 | 2018-12-20 | $358.54 | $787K | +4.0% | +13.2% | +13.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.